2 results
Approved WMOCompleted
To evaluate the safety, tolerability and pharmacokinetics of ascending single and multiple doses of CH-4051.
Approved WMOCompleted
To compare pembrolizumab plus lenvatinib in combination with TACE versus placebo plus TACE with regard to progression-free survival (PFS) per RECIST 1.1 assessed by blinded, independent central review (BICR)